Arylpyrazole Ethers Inhibit LTA4H Enzyme
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by leukotrienes, such as asthma and cardiovascular diseases, lack effective inhibitors of leukotriene A4 hydrolase (LTA4H), which are crucial for managing inflammation and related pathologies.
Innovation Solution
Development of novel arylpyrazole ether compounds that inhibit LTA4H, offering a pharmaceutical solution for treating allergic, pulmonary, fibrotic, inflammatory, and cardiovascular diseases by blocking leukotriene production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for leukotriene-mediated diseases are used, then existing therapeutic options are available, but effective inhibition of leukotriene A4 hydrolase is lacking
Solution Approach 1:
The patent segments the leukotriene pathway by developing specific inhibitors for LTA4H, a key enzyme in leukotriene synthesis. This allows targeted intervention at a specific step in the pathway, providing reliable LTA4H inhibition while maintaining versatility through multiple compound options with different structural characteristics
Solution Approach 2:
The patent employs parameter changes by modifying molecular structures of arylpyrazole ethers to optimize LTA4H inhibition. By varying structural parameters (substituents, ring systems, linkers), the patent achieves effective inhibition while providing multiple therapeutic options with potentially different pharmacokinetic and pharmacodynamic profiles
2Reliability
If novel arylpyrazole ether compounds are developed to inhibit LTA4H, then effective inhibition of leukotriene production is achieved, but the complexity of drug development increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at particular positions in the arylpyrazole ether core structure. This allows the molecules to achieve effective LTA4H inhibition through localized interactions with the enzyme active site, rather than requiring complex overall molecular structures
Solution Approach 2:
The patent uses composite molecular structures combining arylpyrazole ether cores with various substituent groups. This composite approach allows the molecules to achieve effective LTA4H inhibition through synergistic interactions between different structural elements, balancing complexity with therapeutic effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The arylpyrazole ether compounds effectively inhibit LTA4H, providing a therapeutic approach to manage leukotriene-mediated disorders, including asthma and cardiovascular diseases by reducing inflammation and leukotriene production.
Implementation Method 1
The present invention provides novel compounds which inhibit leukotriene A4 hydrolase (LTA4H) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of leukotrienes
Data Source
AI summary
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the Compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.